Hema Now
In this episode of Hema Now, we take a deep dive into myeloproliferative neoplasms (MPN), with a particular focus on myelofibrosis, one of the most complex and challenging MPNs to manage. Ciro Rinaldi discusses what distinguishes myelofibrosis from other chronic MPNs, the biological drivers of disease progression, and the critical role of inflammation and the bone marrow microenvironment. The conversation also explores emerging combination therapies, translational research hurdles, and how the management of myelofibrosis may evolve over the next decade.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (42 mins)
Ciro Rinaldi is an Honorary Professor of Haematology at the University of Lincoln, UK. He also serves as the Deputy Chief Medical Officer as well as Director of Research and Innovation at Lincolnshire Community and Hospitals NHS Group, UK. His work spans translational research and clinical practice, with significant contributions to clinical trials and therapeutic development in myelofibrosis and related disorders.
Timestamps:
00:00 – Introduction
00:59 – Myeloproliferative neoplasms
04:00 – Myelofibrosis
09:58 – Ciro’s interest in the field
13:39 – Disease drivers & progression to aggressive states
17:40 – Inflammation and the bone marrow environment
22:19 – Novel targets
27:45 – Splenomegaly and MPNs
32:19 – Translational research
36:25 – Future of myelofibrosis management
38:51 – Ciro’s three magic wishes
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
